Imatinib

Small Intestine Cancer

European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 81/ 100

Competitive context

21 Active assets in the Small Intestine Cancer cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide National Cancer Institute (NCI)	Phase 2	BB
ETOPOSIDE Cancer Research UK	Phase 2	BB
VINCRISTINE SULFATE Cancer Research UK	Phase 2	BB
FILGRASTIM Cancer Research UK	Phase 2	BB
Carboplatin National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.